Stock AnalizWest Pharmaceutical Services (WST) earnings for the quarter ended September 2026: EPS beats estimates
West Pharmaceutical Services reported results for the quarter ended September 2026 on October 29, 2026. Adjusted earnings per share came in at $2.66 against the analysts’ average forecast of $2.20, a beat of 21.1%.
Revenue for the quarter was $874 million, up 8.7% from $805 million in the same quarter a year earlier.
The market’s verdict: the stock rose 3.2% on the first trading day after the report.
The last four quarters
West Pharmaceutical Services has beaten the analysts’ EPS forecast in 4 of the last 4 quarters.
| Quarter | EPS | Forecast | Surprise | Revenue growth | Price reaction |
|---|---|---|---|---|---|
| Sep 2026 | $2.66 | $2.20 | +21.1% | +9% | +3.2% |
| Jun 2026 | $2.37 | $2.08 | +13.9% | +14% | −8.4% |
| Mar 2026 | $2.13 | $1.68 | +27.1% | +21% | +11.6% |
| Sep 2025 | $1.96 | $1.71 | +14.6% | +8% | +7.4% |
What comes next
Analysts expect EPS of $2.28 for the next quarter on average and $9.46 for the fiscal year ending December 31, 2026.
The average analyst price target is $471.00, 13% above the current price of $416.42.
Valuation and score
West Pharmaceutical Services scores 2.6 out of 5 overall on Stock Analiz (average), trades at a trailing P/E of about 46.7, and its intrinsic value under moderate assumptions is about 71% below the current market value. Full West Pharmaceutical Services analysis with 10 years of financials
Frequently asked questions
What was West Pharmaceutical Services’s EPS for the quarter ended September 2026?
$2.66 adjusted per share, against an analyst consensus of $2.20.
How much revenue did West Pharmaceutical Services report?
$874 million, up 8.7% year over year.
More
This report was written automatically from the published numbers within hours of the release. It is information, not investment advice.